We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder (REED)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01455961
First Posted: October 20, 2011
Last Update Posted: August 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
October 17, 2011
October 20, 2011
August 21, 2014
November 2011
April 2012   (Final data collection date for primary outcome measure)
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date. [ Time Frame: 1st of January 2009 to 31st of December 2010. ]
Same as current
Complete list of historical versions of study NCT01455961 on ClinicalTrials.gov Archive Site
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date. [ Time Frame: 1st of January 2009 to 31st of December 2010. ]
  • Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date [ Time Frame: 1st of January 2009 to 31st of December 2010. ]
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date [ Time Frame: 1st of January 2009 to 31st of December 2010. ]
Same as current
Not Provided
Not Provided
 
An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder
An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR
The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.
An epidemiological registry study to evaluate clinical practice treatment in patients with Bipolar Disorder treated with quetiapine XR and/or quetiapine IR
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
All patients who have been hospitalised in Sweden at least once since 1987 with a diagnosis during hospitalisation of Bipolar Disorder.
Bipolar Disorder
Not Provided
Not Provided
Carlborg A, Thuresson M, Ferntoft L, Bodegard J. Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients. Ther Adv Psychopharmacol. 2015 Feb;5(1):13-21. doi: 10.1177/2045125314560740.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16000
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of BD.

Exclusion Criteria:

  • Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01455961
VD-NS-1101
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Andreas Carlborg, MD Department of Clinical Neuroscience, Karolinska Institutet 171 76 Stockholm
AstraZeneca
August 2014